Los Angeles Capital Management
EGRX

Los Angeles Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Los Angeles Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-132,606
Closed -$743K – 1328
2024
Q2 		$743K Sell
132,606
-59,126
-31% -$258K ﹤0.01% 748
2024
Q1 		$1M Buy
191,732
+100,470
+110% +$551K ﹤0.01% 687
2023
Q4 		$477K Buy
91,262
+36,982
+68% +$365K ﹤0.01% 885
2023
Q3 		$856K Sell
54,280
-15,404
-22% -$277K ﹤0.01% 689
2023
Q2 		$1.35M Sell
69,684
-4,931
-7% -$117K 0.01% 582
2023
Q1 		$2.12M Buy
74,615
+32,339
+76% +$960K 0.01% 485
2022
Q4 		$1.24M Buy
+42,276
New +$1.34M 0.01% 645
2022
Q3 		– Sell
-34,358
Closed -$1.53M – 1408
2022
Q2 		$1.53M Sell
34,358
-9,036
-21% -$415K 0.01% 597
2022
Q1 		$2.15M Buy
43,394
+4,476
+12% +$215K 0.01% 509
2021
Q4 		$1.98M Sell
38,918
-21
-0.1% -$1.09K 0.01% 517
2021
Q3 		$2.17M Sell
38,939
-3,770
-9% -$185K 0.01% 515
2021
Q2 		$1.83M Buy
42,709
+25,050
+142% +$1.03M 0.01% 609
2021
Q1 		$737K Sell
17,659
-2,115
-11% -$98.2K ﹤0.01% 1048
2020
Q4 		$921K Sell
19,774
-18,375
-48% -$859K ﹤0.01% 976
2020
Q3 		$1.62M Sell
38,149
-7,637
-17% -$334K 0.01% 635
2020
Q2 		$2.2M Buy
45,786
+13,681
+43% +$683K 0.01% 591
2020
Q1 		$1.48M Buy
32,105
+10,910
+51% +$547K 0.01% 615
2019
Q4 		$1.27M Hold
21,195
– – 0.01% 765
2019
Q3 		$1.2M Buy
21,195
+6,530
+45% +$367K 0.01% 764
2019
Q2 		$817K Hold
14,665
– – ﹤0.01% 904
2019
Q1 		$740K Hold
14,665
– – ﹤0.01% 962
2018
Q4 		$591K Buy
14,665
+2,115
+17% +$109K ﹤0.01% 916
2018
Q3 		$870K Buy
+12,550
New +$951K ﹤0.01% 918

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Los Angeles Capital Management's EGRX Position: Q3 2024 in Review

Los Angeles Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 132,606 shares — an estimated $743K sold.

Los Angeles Capital Management first reported a position in EGRX in Q3 2018 and held it in 23 quarters. The position peaked at $2.2M in Q2 2020. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.

  • Los Angeles Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
  • Los Angeles Capital Management sold 132,606 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $743K.
  • Los Angeles Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2018 and held it in 23 quarters.
  • Los Angeles Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $2.2M in Q2 2020.
  • 65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.

Based on Los Angeles Capital Management's 13F filing for Q3 2024, filed 4 Nov 2024.